Filtered By:
Cancer: Lung Cancer
This page shows you your search results in order of date. This is page number 18.
Order by Relevance | Date
Total 37399 results found since Jan 2013.
With Comparable Outcomes, Should Early Stage Lung Cancer Be A Contraindication to Lung Transplant?
CONCLUSIONS: One- and 5-year survival rates were comparable between LTx recipients with incidentally noted pathological Stage I NSCLC and contemporary recipients without cancer. All cancer-related mortality occurred in recipients with incidentally noted advanced NSCLC. These results suggest that patients with pathological Stage I lung cancer at the time of transplant have outcomes comparable to those without cancer findings at the time of transplant.PMID:37704001 | DOI:10.1016/j.athoracsur.2023.09.002
Source: The Annals of Thoracic Surgery - September 13, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Connor S Spies Timothy N Ochoa Arya Pontula Chelsea S Harris Laurie D Snyder Elizabeth N Pavlisko Matthew G Hartwig Source Type: research
Identification of DNA variants at ultra-low variant allele frequencies via Taq polymerase cleavage of wild-specific blockers
Anal Bioanal Chem. 2023 Sep 13. doi: 10.1007/s00216-023-04931-0. Online ahead of print.ABSTRACTDetecting mutations related to tumors holds immense clinical significance for cancer diagnosis and treatment. However, the presence of highly redundant wild DNA poses a challenge for the advancement of low-copy mutant ctDNA genotyping in cancer cases. To address this, a Taqman qPCR strategy to identify rare mutations at low variant allele fractions (VAFs) has been developed. This strategy combines mutant-specific primers with wild-specific blockers. Diverging from other blocker-mediated PCRs, which rely on primer-induced strand d...
Source: Analytical and Bioanalytical Chemistry - September 13, 2023 Category: Chemistry Authors: Zhaocheng Liu Xiushuai Li Rui Zhang Li Ji Lingli Gong Yong Ji Fengsheng Zhou Ying Yin Koukou Li Ping Sun Zhening Pu Qing Wang Jian Zou Source Type: research
Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non-Small Cell Lung Cancer
CONCLUSIONS: ctDNA monitoring during induction chemoIO can inform treatment outcomes in patients with advanced NSCLC. Importantly, monitoring remains feasible and informative for patients missing baseline ctDNA. ctDNA testing during induction chemoIO identifies patients at higher risk for disease progression and may inform patient selection for novel personalized maintenance or second line treatment strategies.PMID:37702716 | DOI:10.1158/1078-0432.CCR-23-1578
Source: Clinical Cancer Research - September 13, 2023 Category: Cancer & Oncology Authors: Bruna Pellini Russell W Madison Merrida Childress Shoshana T Miller Ole Gjoerup Jason Cheng Richard S P Huang Michael Krainock Pratyush Gupta Wei Zou David S Shames Solomon Moshkevich Marcus Ballinger Minetta C Liu Amanda Young Minu K Srivastava Geoffrey Source Type: research
Fenretinide induces apoptosis and synergises the apoptosis inducing effect of gemcitabine through inhibition of key signalling molecules involved in A549 cell survival in in silico and in vitro analyses
In conclusion, Akt may be exploited as a good target for induction of apoptosis in A549 cells and fenretinide has great potentials to fulfil this task. The mechanism by which fenretinide boosts the apoptosis inducing effects of gemcitabine, which is likely expected to be via inhibiting mTORC2 downstream targets. However, docking investigation revealed that fenretinide lacks specificity as it may also interact with several secondary targets beside Akt.PMID:37704095 | DOI:10.1016/j.cellsig.2023.110885
Source: Cellular Signalling - September 13, 2023 Category: Cytology Authors: Hazem A Al-Bustany Hawzheen A Muhammad Mahmoud A Chawsheen Phil R Dash Source Type: research
Nicaraven Exerts a Limited Effect on Radiation-Induced Inhibition of Tumor Growth in a Subcutaneous Murine Tumor Model
Radiat Res. 2023 Sep 13. doi: 10.1667/RADE-22-00212.1. Online ahead of print.ABSTRACTNicaraven selectively protects normal tissue from radiation-induced injury. To further develop the clinical application of nicaraven for mitigating the side effects of cancer radiotherapy, we investigated the potential effect of nicaraven administration in radiation-induced inhibition of tumor growth. A subcutaneous tumor model was established in mice by the injection of Lewis lung cancer cells at the back of the chest. X-ray radiation was delivered to the thoracic area and different doses of nicaraven (0, 20, 50, 100 mg/kg) were administr...
Source: Radiation Research - September 13, 2023 Category: Physics Authors: Lina Abdelghany Yong Xu Reiko Sekiya Chen Yan Keiichi Jingu Tao-Sheng Li Source Type: research
A novel synthesized prodrug of gemcitabine based on oxygen-free radical sensitivity inhibited the growth of lung cancer cells
J Biomed Res. 2023 Sep 28:1-12. doi: 10.7555/JBR.37.20230022. Online ahead of print.ABSTRACTIn the present study, we introduced the H 2O 2-sensitive thiazolidinone moiety at the 4th amino group of gemcitabine (GEM) to synthesize a new target compound named GEM-ZZQ, and then we confirmed its chemical structure by nuclear magnetic resonance spectroscopy. We further confirmed that GEM-ZZQ had a good chemical stability in different pH solutions in vitro and that it could be activated by H 2O 2 to release GEM. Pharmacodynamic studies revealed that the growth inhibition of human normal epithelial cells was weaker by GEM-ZZQ than...
Source: Biomed Res - September 13, 2023 Category: Research Authors: Xinlu Chai Yuting Meng Wei Ge Juan Wang Fei Li Xue Jun Wang Xuerong Wang Source Type: research
Erratum: Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial
J Clin Oncol. 2023 Sep 13:JCO2301849. doi: 10.1200/JCO.23.01849. Online ahead of print.NO ABSTRACTPMID:37703508 | DOI:10.1200/JCO.23.01849
Source: Clinical Lung Cancer - September 13, 2023 Category: Cancer & Oncology Source Type: research
Mesenteric Castleman Disease Misdiagnosed as Lymph Node Metastasis of Rectal Cancer on 18F-FDG PET/CT
Clin Nucl Med. 2023 Sep 7. doi: 10.1097/RLU.0000000000004832. Online ahead of print.ABSTRACTTwo years ago, a 64-year-old man underwent an 18F-FDG PET/CT for staging rectal cancer. Besides the hypermetabolic rectal lesion, the image revealed a mesenteric lymph node with intense activity and multiple lung nodules with slight FDG uptake, which were highly suspected of metastases. After surgery and multiple cycles of chemotherapy, the follow-up 18F-FDG PET/CT showed remission of all lesions except for the enlarged mesenteric lymph node with higher metabolic activity. Serum CEA remained normal during the follow-up. Postoperativ...
Source: Clinical Lung Cancer - September 13, 2023 Category: Cancer & Oncology Authors: Meixi Liu Jiaolin Zhou Wenjia Zhu Li Huo Wuying Cheng Source Type: research
18F-FDG PET/CT Imaging of Pulmonary Hamartomas: Metabolic and Functional Characterization
We report the case of a 49-year-old woman recently diagnosed with left breast cancer with suspicious left axillary lymph nodes. 18F-FDG PET/CT showed well-circumscribed, lobulated, low-attenuation soft tissue mass in the right lower lobe lung with mild to no significant metabolic activity. CT-guided biopsy showed the lesion composed of fat, cartilage, and smooth muscle, admixed with fibroconnective tissue. The findings are consistent with pulmonary hamartoma. The presence of fat in a well-circumscribed solitary pulmonary nodule along with low metabolic activity helps in the characterization of the lesion, which can alter p...
Source: Clinical Lung Cancer - September 13, 2023 Category: Cancer & Oncology Authors: Sharjeel Usmani Anjali Jain Syed M J Akhter Khulood Al Riyami Sofiullah Abubakar Asiya Al Busaidi Source Type: research
Clinico-pathological characteristics of IGFR1 and VEGF-A co-expression in early and locally advanced-stage lung adenocarcinoma
CONCLUSIONS: These results suggest that IGFR1+&VEGF-A+ is expected to be a disadvantageous factor for prognosis in the subgroup of EGFR mutation in patients with early and locally advanced-stage lung adenocarcinoma. What's more, this study may provide the theoretical possibility to screen optimal population for a combination therapy with anti-VEGF and anti-IGFR1 in patients with early and locally advanced-stage lung adenocarcinoma.PMID:37702808 | DOI:10.1007/s00432-023-05371-0
Source: Clinical Lung Cancer - September 13, 2023 Category: Cancer & Oncology Authors: Wenting Liu Junling Xia Qingwu Du Jingya Wang Ting Mei Tingting Qin Source Type: research
Prevalence of mutations in common tumour types in Northern England and comparable utility of national and international Trial Finders
CONCLUSIONS: Regional differences in mutations may exist with advanced stage accounting for prevalence of specific mutations. A national Trial Finder shows utility in finding targeted trials whilst commercial sequencing reports may over-report 'actionable' mutations. Understanding local prevalence and trial availability could increase enrolment onto matched early phase trials.PMID:37702806 | DOI:10.1007/s00432-023-05365-y
Source: Clinical Lung Cancer - September 13, 2023 Category: Cancer & Oncology Authors: S Rae E Plummer L Fitzgerald L Hogarth A Bridgewood L Brown-Schofield J Graham S Haigh C McAnulty Y Drew N Haris S Bashir R Plummer A Greystoke Source Type: research
Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non-Small Cell Lung Cancer
CONCLUSIONS: ctDNA monitoring during induction chemoIO can inform treatment outcomes in patients with advanced NSCLC. Importantly, monitoring remains feasible and informative for patients missing baseline ctDNA. ctDNA testing during induction chemoIO identifies patients at higher risk for disease progression and may inform patient selection for novel personalized maintenance or second line treatment strategies.PMID:37702716 | DOI:10.1158/1078-0432.CCR-23-1578
Source: Clinical Lung Cancer - September 13, 2023 Category: Cancer & Oncology Authors: Bruna Pellini Russell W Madison Merrida Childress Shoshana T Miller Ole Gjoerup Jason Cheng Richard S P Huang Michael Krainock Pratyush Gupta Wei Zou David S Shames Solomon Moshkevich Marcus Ballinger Minetta C Liu Amanda Young Minu K Srivastava Geoffrey Source Type: research
The Prognostic and Functional Impact of Sprouty 2 Expression in Non-small Cell Lung Cancer
CONCLUSION: Spry2 expression was lower in tumor tissues than in normal lung parenchyma. Increased expression of Spry2 is associated with poor prognosis. There were no significant associations between epidermal growth factor receptor, anaplastic lymphoma kinase, or c-ros oncogene 1 rearrangement and Spry2 expression. Despite the absence of KRAS mutational analysis, the clinical and epidemiological features of patients suggested that KRAS mutation might be an underlying determinant factor of the functional role of Spry2 in non-small cell lung cancer.PMID:37700432 | DOI:10.1097/COC.0000000000001044
Source: Clinical Lung Cancer - September 13, 2023 Category: Cancer & Oncology Authors: Yusuf Acikgoz Fatma Unal Yildirim Selin Akturk Esen Gokhan Ucar Yakup Ergun Oznur Bal Mutlu Dogan Dogan Uncu Source Type: research
Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration
CONCLUSIONS: Moderate-certainty evidence suggests that antioxidant vitamin and mineral supplementation (AREDS: vitamin C, E, beta-carotene, and zinc) probably slows down progression to late AMD. People with intermediate AMD have a higher chance of benefiting from antioxidant supplements because their risk of progression is higher than people with early AMD. Although low-certainty evidence suggested little effect with lutein/zeaxanthin alone compared with placebo, exploratory subgroup analyses from one large American study support the view that lutein/zeaxanthin may be a suitable replacement for the beta-carotene used in th...
Source: Cochrane Database of Systematic Reviews - September 13, 2023 Category: General Medicine Authors: Jennifer R Evans John G Lawrenson Source Type: research
Molecular docking analysis of mefluhybenamine with lung cancer targets
Bioinformation. 2022 Dec 31;18(12):1186-1191. doi: 10.6026/973206300181186. eCollection 2022.ABSTRACTLung cancer is the most prevalent type of cancer worldwide, with 2.21 million cases and 1.80 million fatalities in 2020. The main factor influencing lung cancer is smoking, and the most common form of lung cancer, non-small cell lung cancer (NSCLC), accounts for around 80% of instances compared to small cell carcinoma, and about 75% of patients are already in an advanced stage when they are detected. Despite significant early detection and therapy improvements, the five-year survival rate for NSCLC is not encouraging. There...
Source: Bioinformation - September 13, 2023 Category: Bioinformatics Authors: Youssef S Alghamdi Source Type: research
